Studies in Galveston.
ACTG A5197 is a study looking at a "therapeutic vaccine" to see what kind of role it may have in the long-term control of HIV. Therapeutic vaccines are for individuals that already have HIV. These vaccines are intended to slow the progression of HIV in the body. Individuals who participate in this study will be randomly assigned (by chance, like flipping a coin) to receive 3 injections of the vaccine or a placebo. Then, participants will stop taking their HIV meds for 16 weeks. During this interruption, researchers will look at how long the vaccine continues to work. Study participants then have the option to restart meds or continue to stay off them through week 87 of the study. The final phase of the study is a long-term follow-up lasting about 3 years. People interested in this study must be 18 to 50 years old and HIV+. Interested individuals must have a T count of 500 or greater. They also must have a viral load less than 50 (and less than 500 for at least 2 years). Contact Gerianne Casey at 409-747-0214 or 1-877-324-2288 for complete details on this study.
ACT6 A5146 is a study that will examine the effect of adjusting the dose of a patient's HIV protease inhibitor (PI) on controlling HIV viral load levels. A PI is an HIV reed that interferes with HIV's ability to reproduce. Specifically, this study will examine whether higher doses of PI drugs control HIV better than standard doses of PI drugs that HIV+ people already receive. The researchers want to know if the increased amount of PIs is better at lowering the amount of HIV in the blood. Each person's levels of PI drugs will be adjusted using a measurement called "therapeutic drug monitoring" (TDM). Individuals interested in participating in this study must have a viral load greater than 1,000 and must be taking HIV medications that include a PI. Contact Gerianne Casey at 409-747-0214 or 1-800-324-2288 for complete information on this study.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||New medications in progress for HIV; vicraviroc; therapeutic vaccine; protease inhibitor|
|Publication:||HIV Treatment: ALERTS!|
|Date:||Apr 1, 2005|
|Previous Article:||SMART Study.|
|Next Article:||The 14th Conference on Retroviruses and Opportunistic Infections (CROI): Los Angeles, February 25th-28th.|